A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment

This study looks at whether adjusting treatment based on minimal residual disease (MRD) — tiny amounts of cancer cells that remain after initial treatment — improves outcomes in patients newly diagnosed with multiple myeloma (a type of blood cancer) who still have detectable disease after initial therapy. **You may be eligible if...** - You are 18 or older with newly diagnosed multiple myeloma - You achieved at least a partial response (meaningful improvement) after at least one prior treatment regimen - You are willing to comply with contraception requirements and study visits **You may NOT be eligible if...** - You have smoldering or asymptomatic myeloma, or a precursor condition (MGUS) - Your disease has relapsed and become resistant to salvage therapy - Your disease never responded to any treatment (primary refractory myeloma) - You have conditions that would make following the protocol unsafe or impractical Talk to your doctor to see if this trial is right for you.